Arjuna Capital bought a new position in Waters Co. (NYSE:WAT - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 1,204 shares of the medical instruments supplier's stock, valued at approximately $447,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. boosted its stake in Waters by 70.7% during the third quarter. Principal Financial Group Inc. now owns 656,019 shares of the medical instruments supplier's stock worth $236,095,000 after acquiring an additional 271,804 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of Waters in the 4th quarter worth approximately $42,114,000. Raymond James Financial Inc. bought a new position in Waters in the fourth quarter worth approximately $40,404,000. JPMorgan Chase & Co. lifted its position in Waters by 37.2% during the third quarter. JPMorgan Chase & Co. now owns 305,661 shares of the medical instruments supplier's stock valued at $110,005,000 after purchasing an additional 82,865 shares in the last quarter. Finally, Impax Asset Management Group plc grew its stake in shares of Waters by 10.6% during the 4th quarter. Impax Asset Management Group plc now owns 714,155 shares of the medical instruments supplier's stock valued at $264,937,000 after acquiring an additional 68,509 shares during the period. Hedge funds and other institutional investors own 94.01% of the company's stock.
Waters Stock Performance
Shares of WAT stock traded down $5.94 on Wednesday, hitting $372.92. The company had a trading volume of 371,933 shares, compared to its average volume of 438,774. The company has a quick ratio of 0.65, a current ratio of 0.94 and a debt-to-equity ratio of 1.14. The company has a 50-day moving average price of $391.16 and a 200-day moving average price of $369.78. Waters Co. has a twelve month low of $279.24 and a twelve month high of $423.56. The firm has a market cap of $22.16 billion, a P/E ratio of 34.82, a price-to-earnings-growth ratio of 3.79 and a beta of 1.00.
Waters (NYSE:WAT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 EPS for the quarter, beating the consensus estimate of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. As a group, equities research analysts predict that Waters Co. will post 12.86 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on WAT shares. Barclays raised Waters from an "underweight" rating to an "equal weight" rating and upped their price objective for the stock from $360.00 to $415.00 in a research note on Monday, February 10th. Wells Fargo & Company boosted their price objective on Waters from $415.00 to $420.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Sanford C. Bernstein raised shares of Waters from a "market perform" rating to an "outperform" rating and set a $430.00 price objective for the company in a research note on Friday, January 10th. Bank of America reduced their target price on shares of Waters from $430.00 to $410.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Finally, StockNews.com lowered shares of Waters from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Eleven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Waters has an average rating of "Hold" and a consensus target price of $391.07.
Check Out Our Latest Report on WAT
Waters Company Profile
(
Free Report)
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Stories
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
